GBA1 and Parkinson disease: A phase I study is currently recruiting to evaluate PR001A, a viral vector-based therapy to deliver GBA which rescues GCase activity and reduces α-synuclein levels in cell and mouse models [180], in patients with moderate to severe PD and GBA variants (NCT04127578).